What are the main functions and effects of cabozantinib? Which cancer types are suitable for

Cabozantinib (Cabozantinib) is an oral targeted drug that is a multi-target tyrosine kinase inhibitor and has a wide range of anti-tumor effects. It exerts anti-cancer effects by inhibiting the growth and spread of tumor cells. The main effect of cabozantinib is to control the progression of cancer by inhibiting tumor-related angiogenesis and tumor cell proliferation, and can improve patients' survival and quality of life. The drug has been approved to treat many types of cancer and has shown significant efficacy in treating advanced cancers.

1. Anti-tumor mechanism

Cabotinib inhibits the activity of multiple tyrosine kinases, includingMET, VEGFR, AXL, RET, KIT, etc., exert their anti-tumor effects. In particular, cabozantinib inhibits the MET receptor kinase, which plays a key role in tumor metastasis, thereby slowing the spread of tumors. In addition, cabozantinib can also inhibit the vascular endothelial growth factor receptor (VEGFR), prevent the formation of new blood vessels in tumors, cut off the blood supply of tumors, and achieve the purpose of inhibiting tumor growth.

2. Indications

Cabozantinib is mainly used to treat the following types of cancer:

Renal cell carcinoma (RCC): Cabozantinib is one of the effective drugs for the treatment of advanced or metastatic renal cell carcinoma. It is used as a first- or second-line treatment, especially for patients whose disease has progressed despite other treatments. Clinical studies have shown that cabozantinib can significantly improve progression-free survival (PFS) and overall survival (OS).

Hepatocellular carcinoma (HCC): Cabozantinib has significant efficacy in patients with advanced or unresectable hepatocellular carcinoma, especially those whose disease has not been controlled after other treatments such as sorafenib. Cabozantinib helps control tumor growth and prolong patient survival by reducing tumor blood supply and inhibiting tumor angiogenesis.

Thyroid Cancer: Cabozantinib is approved to treat advanced dedifferentiated thyroid cancer (DTC), particularly in those cases that cannot be controlled with surgery or radiation therapy. Cabozantinib can effectively inhibit the proliferation of thyroid cancer cells, slow down the progression of tumors, and improve the quality of life of patients.

Other indications: Cabozantinib is also used in some clinical trials to treat other cancer types, such as non-small cell lung cancer (NSCLC), ovarian cancer, and breast cancer. Its clinical potential is also constantly being explored, especially for patients with refractory or advanced cancers.

3. Therapeutic effect

Cabozantinib has shown good therapeutic effects in different types of cancer, especially renal cell carcinoma and hepatocellular carcinoma. For patients with renal cell carcinoma, cabozantinib can effectively delay tumor progression and improve the overall survival of patients, and its therapeutic effect on patients with advanced renal cell carcinoma is better than traditional treatments. In the treatment of hepatocellular carcinoma, cabozantinib has shown good clinical efficacy by improving patient survival and controlling tumor growth. In addition, cabozantinib's multiple mechanisms of action in targeted therapy also make it a treatment option for some advanced and refractory tumors.

4. Side Effects and Management

Although cabozantinib is effective in treating tumors, it may also cause some side effects. Common side effects include diarrhea, high blood pressure, fatigue, abnormal liver function, and hand-foot skin reaction. Patients need to regularly monitor blood pressure, liver function and electrolyte levels while using cabozantinib so that treatment options can be adjusted in a timely manner. In addition, when diarrhea occurs, patients can use antidiarrheal drugs for symptomatic treatment and maintain adequate fluid intake. For patients with high blood pressure, a combination of antihypertensive drugs may be needed for control.

Cabozantinib, as a multi-target tyrosine kinase inhibitor, has shown significant efficacy in the treatment of a variety of advanced cancers, especially in the treatment of renal cell carcinoma, hepatocellular carcinoma and thyroid cancer. Although there are certain side effects, patients can give full play to the advantages of its treatment, prolong survival and improve quality of life through appropriate management and monitoring under the guidance of doctors.

Reference:https://en.wikipedia.org/wiki/Cabozantinib